ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer

RCT (n=298) terminated early showed no significant difference in overall survival at 3 years, but significantly better locoregional control with concurrent cisplatin vs. cetuximab (cumulative incidence locoregional failures at 3 years = 23% vs 9%, respectively, p=0.0036).

Journal of Clinical Oncology